Patents by Inventor Marc Tessier-Lavigne

Marc Tessier-Lavigne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6096866
    Abstract: Netrins, nucleic acids which encode netrin proteins and hybridization reagents, probes and primers capable of hybridizing with netrin genes and methods for screening chemical libraries for lead compounds for pharmacological agents are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 1, 2000
    Assignees: The Regents of the University of California, Columbia University
    Inventors: Marc Tessier-Lavigne, Tito Serafini, Timothy Kennedy, Marysia Placzek, Thomas Jessell, Jane Dodd
  • Patent number: 6087326
    Abstract: Compositions for identifying lead compounds for pharmacological agents useful in the diagnosis or treatment of neurological disease or injury include mixtures comprising an isolated netrin and an isolated natural netrin receptor such as "Deleted in Colorectal Carcinoma" (DCC) and neogenin. The general methods involve incubating a mixture of an isolated mammalian netrin, an isolated natural mammalian netrin receptor, and a candidate pharmacological agent, and determining if the presence of the agent modulates the binding of the netrin to the receptor.
    Type: Grant
    Filed: January 15, 1998
    Date of Patent: July 11, 2000
    Assignee: The Regents of the University of California
    Inventors: Lindsay Hinck, Kasuko Masu, Masayuki Masu, David Leonardo, Marc Tessier-Lavigne
  • Patent number: 6054293
    Abstract: The invention provides methods and compositions relating to two classes of semaphorin receptors, SR1 and SR2. The polypeptides may be produced recombinantly from transformed host cells from the disclosed SR encoding nucleic acids or purified from human cells. The invention provides isolated SR hybridization probes and primers capable of specifically hybridizing with the disclosed SR genes, SR-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: September 24, 1997
    Date of Patent: April 25, 2000
    Assignee: The Regents of the University of California
    Inventors: Marc Tessier-Lavigne, Zhigang He, Hang Chen
  • Patent number: 6046015
    Abstract: Disclosed are methods and compositions for identifing agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the agent modulates the interaction of the Robo and Slit polypeptides.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: April 4, 2000
    Assignee: The Regents of the University of California
    Inventors: Corey S. Goodman, Thomas Kidd, Katja Brose, Marc Tessier-Lavigne
  • Patent number: 6017714
    Abstract: Netrin proteins, nucleic acids which encode netrin proteins and hybridization reagents, probes and primers capable of hybridizing with netrin genes and methods for screening chemical libraries for lead compounds for pharmacological agents are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 25, 2000
    Assignees: The Regents of the University of California, Columbia University
    Inventors: Marc Tessier-Lavigne, Tito Serafini, Timothy Kennedy, Marysia Placzek, Thomas Jessell, Jane Dodd
  • Patent number: 5824775
    Abstract: Specific netrin proteins, nucleic acids which encode netrin proteins and hybridization reagents, probes and primers capable of hybridizing with netrin genes and methods for screening chemical libraries for lead compounds for pharmacological agents useful in the diagnosis or treatment of disease associated undesirable cell growth are provided. An exemplary screen involves forming a mixture comprising a recombinant netrin protein, a natural intracellular netrin protein binding target, and a candidate pharmacological agent; incubating the mixture under conditions whereby, but for the presence of said candidate pharmacological agent, said netrin protein selectively binds said binding target; and detecting the presence or absence of specific binding of said netrin protein to said binding target.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: October 20, 1998
    Assignee: The Regents of the University of California
    Inventors: Candace Swimmer, Anne Shyjan, David Leonardo, Yuan Zhang, Timothy Kennedy, Tito Serafini, Marc Tessier-Lavigne
  • Patent number: 5747262
    Abstract: Compositions for identifying lead compounds for pharmacological agents useful in the diagnosis or treatment of neurological disease or injury include mixtures comprising an isolated netrin and an isolated natural netrin receptor such as "Deleted in Colorectal Carcinoma" (DCC) and neogenin. The general methods involve incubating a mixture of an isolated mammalian netrin, an isolated natural mammalian netrin receptor, and a candidate pharmacological agent, and determining if the presence of the agent modulates the binding of the netrin to the receptor.
    Type: Grant
    Filed: October 16, 1995
    Date of Patent: May 5, 1998
    Assignee: The Regents of the University of California
    Inventors: Lindsay Hinck, Kasuko Masu, Masayuki Masu, David Leonardo, Marc Tessier Lavigne
  • Patent number: 5565331
    Abstract: A novel classes of neural axon outgrowth promoting and orienting proteins, nucleic acids encoding such proteins and receptors which selectively bind such proteins are disclosed. The disclosed neural axon outgrowth promoting and orienting proteins include the laminin-related p75/p78 family; a family of vertebrate proteins which promote axon outgrowth and/or orientation, and p75/p78 family-specific receptors, including receptors found on spinal nerve axons, especially growth cones. Also disclosed are agents including peptides derived from the disclosed neural axon outgrowth promoting proteins capable of effecting axon outgrowth, orientation and regeneration. These agents provide small molecular weight modulators of nerve cell growth useful in the treatment of neurological disease and injury.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: October 15, 1996
    Assignee: The Regents of the University of California
    Inventors: Marc Tessier-Lavigne, Tito Serafini, Timothy Kennedy, Merysia Placzek, Thomas Jessell, Jane Dodd